---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-054288"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2026-08-06T20:08:11+00:00"
generated_at: "2026-08-06T20:09:42.009663+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioLife Q2 rev $28.5M (+21% YoY); GAAP net $45.1M incl $42.4M tax benefit; Repligen deal pending Q4

## Summary
- Total revenue $28.5M, up 21% YoY from $23.4M; GAAP gross margin 64%.
- GAAP net income $45.1M includes $42.4M non-cash tax benefit from valuation allowance release; adjusted net income $4.2M.
- Adjusted EBITDA $7.4M (26% of revenue) vs $5.6M (24%) in Q2 2025.
- On July 21, 2026, BioLife agreed to be acquired by Repligen for ~$1.5B enterprise value; expected close Q4 2026.
- Biopreservation media used in ~250 ongoing commercial CGT clinical trials (>70% market share); embedded in 18 approved therapies.

## SEC filing metadata
- accession: 0001628280-26-054288
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2026-08-06T20:08:11+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828026054288/0001628280-26-054288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828026054288/blfs-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-054288
- JSON: https://secwatch.observer/filing/0001628280-26-054288.json
- Plain text: https://secwatch.observer/filing/0001628280-26-054288.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.